Celltrion stock
Scope
Date
~
-
Korean stock market
Samsung C&T to cancel $2.3 bn worth of treasury shares, stocks up
Samsung C&T Corp.’s share price zoomed on Thursday on news that the company will cancel its entire treasury stock holdings worth about 2.9...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Korean stock market
KB Securities launches AI-based RoboNews on US stocks
South Korea's KB Securities announced the launch of KB RoboNews on Monday, a cutting-edge artificial intelligence (AI) service that provides insight...
Feb 14, 2023 (Gmt+09:00)
-
Korean stock market
Individual investors in S.Korea betting on stock market's decline
Despite South Korea's Kosdaq stock market growing this month following the "January rally," individual investors in the country are still betting on...
Feb 09, 2023 (Gmt+09:00)
-
Regulations
Korea seeks legal system for independent equity research firms
South Korea is set to establish a legal system for independent equity research providers this year to protect individual investors, who could be dam...
Feb 08, 2023 (Gmt+09:00)
-
Korean stock market
Korea Shipbuilding & Offshore Engineering ends fears over stock overhang
Korea Shipbuilding & Offshore Engineering (KSOE), a subholding company for shipbuilding, oil refining and machinery conglomerate HD Hyundai Co. ...
Feb 03, 2023 (Gmt+09:00)
-
IPOs
S.Korea's online K Bank withdraws plan for Kospi listing
South Korea's K Bank has withdrawn its highly anticipated plan to hold an IPO this year in the judgement of a lower corporate value due to the slugg...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Jan 25, 2023 (Gmt+09:00)
-
Pension funds
Bank's retirement pension soars 15% to $107 bn last year
Retirement pensions at banks in the fourth quarter of last year emerged as a haven for money that tried to generate a stable return, shunning away f...
Jan 25, 2023 (Gmt+09:00)
-
Korean stock market
S.Korean stock issuance volume declines 24% in 2022
The volume of stock issuance in South Korea declined sharply last year due to the softening stock market. Amid rising interest rates, the amount of ...
Jan 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
ECM/DCM
S.Korean brokerage lowers stock forecast for S-Oil over poor prospects
South Korea's Eugene Investment & Securities on Monday cut S-Oil Corp.'s target share price from 140,000 won ($113.5) to 133,000 won due to a lo...
Jan 16, 2023 (Gmt+09:00)
-
Foreign exchange
S.Korea to extend trading hours of local forex market
South Korea will extend the trading hours for the local foreign exchange market to attract overseas investors and improve the trading system so that...
Jan 13, 2023 (Gmt+09:00)
-
Korean stock market
Foreigners turn net buyers of Korean stocks as China reopens borders
South Korean stocks are gaining momentum at the beginning of the new year as foreigners have turned net buyers on expectations of China's border reo...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Alternative investments
S.Korea's DLS incurring losses due to stock slump exceed $800 billion
South Korea's derivatives-linked securities that entered the knock-in or loss period due to stock slumps at home and abroad exceeded 1 trillion won ...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Private equity
Korean banks must increase total shareholder returns: Align Partners
South Korean private equity firm Align Partners Capital Management Inc. is set to lead shareholder activism against the country’s top financia...
Jan 02, 2023 (Gmt+09:00)
-
Electric vehicles
Koreans buy $2.7 billion Tesla shares this year, favorite foreign stock
Tesla, Inc. was the investors’ choice in South Korea this year, ahead of other overseas stocks.According to the Korea Securities Depository he...
Dec 27, 2022 (Gmt+09:00)
-
Korean stock market
TIGER KEDI30 ETF tops Korean retail investors’ themed stock buy list
The TIGER KEDI30 ETF has topped the list of the most purchased exchange-traded funds (ETFs) by South Korea’s individual investors in the theme...
Dec 27, 2022 (Gmt+09:00)
-
ECM/DCM
Net assets of S.Korea's ETF rise to $63.1 billion despite stock woes
Despite South Korea's weak stock market this year, the exchange-traded fund (ETF) sector, which marked its 20th anniversary, maintained a clear grow...
Dec 27, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Regulations
S.Korea to introduce mandatory offer for takeover deals
South Korea is set to require a takeover bidder for a listed company to buy stakes held by small shareholders at the same price to be paid to a majo...
Dec 22, 2022 (Gmt+09:00)
-
Regulations
Korea to allow investors to sell stocks at pre-split-off values
South Korea is set to allow individual shareholders to sell their stocks at prices before a split-off if they oppose a company’s separation pl...
Dec 21, 2022 (Gmt+09:00)
-
Korean stock market
Ndream, Wisenut start trading on K-OTC
Shares of South Korea's two tech startups, Ndream and Wisenut, will start trading on Korea's over-the-counter market, or K-OTC, on Thursday, the Kor...
Dec 21, 2022 (Gmt+09:00)
-
Korean stock market
Mirae Asset introduces AI investment info service
Mirae Asset Securities Co. said on Tuesday it had introduced two domestic stock artificial intelligence (AI) reporting services through its mobile t...
Dec 20, 2022 (Gmt+09:00)